MedTrace Logo

Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

NCT05811481 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2023-04-13

No results posted yet for this study

Summary

. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2. To evaluate the safety and prognostic imaging factors of regorofenib in advanced second-line therapy; 3, to explore whether it is necessary to increase the treatment of TACE in the second-line treatment of advanced HCC.

Conditions

Interventions

PROCEDURE

TACE

Transcatheter Arterial Chemoembolization

DRUG

Regorafenib

Regorafenib alone

Sponsors & Collaborators

  • WenBo Guo

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-27
Primary Completion
2024-12-27
Completion
2025-12-27
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05811481 on ClinicalTrials.gov